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Mammography screening in Switzerland: limited evidence from
limited data
Abstract
QUESTIONS UNDER STUDY: In Switzerland controversy exists on how to summarise the evidence
on the efficacy and effectiveness, as well as adverse effects, of mammography screening, and breast
cancer mortality trends are often discussed in the context of the impact of mammography.
PRINCIPLES/METHODS: Single-study publications, meta-analyses, and reports by international expert
groups on mammography screening are reviewed. Breast cancer mortality trends from 1970-2000 are
reported and discussed in the context of the Swiss screening situation. RESULTS: In Switzerland breast
cancer mortality rates for female Swiss nationals aged 50-79 years fell between 1990 and 2000 by some
25% in all language regions. The data from randomised studies in large populations in several countries
with well organised mammography programmes prompt the conclusion that participation in organised
screening programmes with rigorous quality standards reduces breast cancer mortality. The achievable
long-term reduction in breast cancer mortality ranges from 5-20% in the target population provided that
appropriate diagnostic investigation and treatment are available. To achieve this in Switzerland 830 to
3300 women need to be invited to screening for ten years to prevent one death from breast cancer. The
risk-benefit profile of mammography screening is likely to be less favourable if mammographies are
performed outside the context of organised screening programmes. In Switzerland we are now
confronted with growing regional disparities in access to screening mammography which is under
systematic quality control. CONCLUSIONS: The decrease in breast cancer mortality in Switzerland is
most probably due to treatment developments and changes in cause-of-death coding. Public health
measures in Switzerland should aim at regulating quality control for screening mammography,
monitoring mammography use and improving the information on mammography available to women.
For an evidence-based decision regarding health insurance coverage of screening mammography in
2007, large gaps need to be filled. The current coexistence of systematic screening programmes and
opportunistic screening, with distinct regional differences, provides a unique opportunity for research
into the merits and drawbacks of the two approaches.
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Breast cancer is a significant public health
problem worldwide [1] and, with about 1500
deaths annually in the years 1990 to 1999 [2], it is
the most common cause of cancer mortality among
women in Switzerland. In the absence of effective
prevention or curative treatment regardless of the
diagnostic stage, early detection remains an essen-
tial option in reducing the physical and psycho-
logical burden of breast cancer.
Since 1990 and despite rising trends in breast
cancer incidence, breast cancer mortality rates
have started to decline in the US and other indus-
trialised countries [1, 3–5]. In January 2000, the re-
view by Gøtzsche and Olsen in the Lancet trig-
gered intense debate on the effectiveness of mam-
mography screening [6]. They dismissed the re-
sults of the majority of the randomised trials of
mammography screening and claimed that mam-
mography is ineffective. This affected impending
decisions in Switzerland on systematic mammog-
raphy. Since then a number of authors and organ-
isations have re-evaluated the studies and sum-
marised the evidence on the efficacy of mammog-
raphy screening (table 5) [7–15]. 
Questions under study: In Switzerland contro-
versy exists on how to summarise the evidence on
the efficacy and effectiveness, as well as adverse
effects, of mammography screening, and breast
cancer mortality trends are often discussed in the
context of the impact of mammography. 
Principles/methods: Single-study publications,
meta-analyses, and reports by international expert
groups on mammography screening are reviewed.
Breast cancer mortality trends from 1970–2000 are
reported and discussed in the context of the Swiss
screening situation. 
Results: In Switzerland breast cancer mortality
rates for female Swiss nationals aged 50–79 years
fell between 1990 and 2000 by some 25% in all lan-
guage regions. The data from randomised studies
in large populations in several countries with well
organised mammography programmes prompt
the conclusion that participation in organised
screening programmes with rigorous quality stan-
dards reduces breast cancer mortality. The achiev-
able long-term reduction in breast cancer mortal-
ity ranges from 5–20% in the target population
provided that appropriate diagnostic investigation
and treatment are available. To achieve this in
Switzerland 830 to 3300 women need to be invited
to screening for ten years to prevent one death
from breast cancer. The risk-benefit profile of
mammography screening is likely to be less
favourable if mammographies are performed out-
side the context of organised screening pro-
grammes. In Switzerland we are now confronted
with growing regional disparities in access to
screening mammography which is under system-
atic quality control. 
Conclusions: The decrease in breast cancer
mortality in Switzerland is most probably due to
treatment developments and changes in cause-of-
death coding. Public health measures in Switzer-
land should aim at regulating quality control for
screening mammography, monitoring mammog-
raphy use and improving the information on mam-
mography available to women. For an evidence-
based decision regarding health insurance cover-
age of screening mammography in 2007, large
gaps need to be filled. The current coexistence of
systematic screening programmes and opportunis-
tic screening, with distinct regional differences,
provides a unique opportunity for research into the
merits and drawbacks of the two approaches.
Key words: mammography; breast cancer; screen-
ing; public health
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In this article we attempt to clarify the defini-
tions used in discussing mammography screening,
review the evidence on efficacy and effectiveness,
discuss adverse effects and discuss the Swiss situa-
tion with regard to breast cancer mortality and ac-
cess to mammography screening. In this way we
hope to shed light on key issues relevant to the dis-
cussion of screening mammography and to clarify
what the public health community, especially in
Switzerland, should and should not expect from
screening mammography in general and from or-
ganised mammography screening programmes
specifically.
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What is meant by mammography screening?
As this review discusses screening mammog-
raphy only, a clear-cut distinction is necessary
between screening and diagnostic mammography
according to the following definitions.
Screening mammography
A) Mammography screening programme 
or systematic early detection of breast cancer 
using mammography
Systematic early detection of breast cancer
using mammography means a quality-assured pro-
gramme with systematic periodic invitation of all
women in a particular age group (in the target
group) to mammography examination that is cost-
free at the point of delivery. Subsequently, the
terms “systematic mammography”, “mammogra-
phy screening programme” and “organised mam-
mography programmes” will be used interchange-
ably. Here one should note that organised screen-
ing programmes comprise six specific characteris-
tics (table 1) ([9], p. 47).
B) Opportunistic mammography screening 
This means individually chosen access by
asymptomatic women to a mammography exami-
nation that is not a response to an invitation in the
context of a mammography screening programme.
Accordingly, quality assurance aspects (that are
part of a mammography screening programme)
are not uniformly regulated or documented. Also,
comprehensive and cost-free access for all women
– regardless of social or economic background – to
mammography is not guaranteed.
Diagnostic mammography 
By diagnostic mammography we mean the use
of mammography x-ray examinations to determine
whether a breast tumour is present in a woman
having symptoms of, or a predisposition for, breast
cancer. 
Other breast cancer screening methods
Systematic mammography for early detection
of breast cancer has been investigated for over 30
years. Screening mammography has clearly docu-
mented limits of sensitivity and specificity (table 3)
[10, 16–19]. More reliable technologies and meth-
ods for the early detection of breast cancer are the
subject of intensive research efforts, but so far no
alternative method has been sufficiently well eval-
uated to justify a systematic population-based ap-
plication [16, 20]. 
Existence of an explicit policy, with specified age categories, method and interval for screening
Definition of a target population
Definition and existence of a clear responsibility (e.g. management team) for implementation
Definition and existence of a health care team for decisions and care
Definition and existence of a quality assurance structure
Existence of a method for identifying cancer occurrence in the target population (e.g. cancer registries)
Table 1
Features of organised
screening pro-
grammes (adapted
from [9] p. 47).
Efficacy of screening mammography from randomised trials 
The need for randomised trials
To establish the efficacy of any cancer screen-
ing programme we cannot rely on observational
studies, as they are affected by a variety of biases
and confounding factors that may distort com-
parisons [21–24]. The randomised controlled trial
with mortality as the outcome is the only study de-
sign in which these biases can be eliminated [25].
The studies conducted so far have been designed
to detect a reduction in cancer-specific mortality.
Whether population-based early detection of can-
cer should prove its efficacy by a reduction in total
mortality or by a reduction in cancer-specific mor-
tality is a matter of ongoing debate [11, 12, 26, 27].
The study design implications of assessing the
effect on all-cause mortality would be enormous.
Starting in 1994, a large randomised trial to inves-
tigate several cancer screening options simulta-
neously will include more than 140 000 partici-
pants and rely on cancer-specific mortality after an
expected follow-up period of 15 years [25].
Efficacy versus programme efficacy 
Efficacy is commonly used to designate the ef-
fect, usually beneficial, estimated in well con-
ducted randomised trials by comparing the out-
come rates of the group receiving the new inter-
vention with the rates in the group receiving the
standard or no intervention. However, in the case
of screening, efficacy reflects the combined effect
of a sequence of procedures designed to achieve a
reduction in mortality [23]: invitation to screening,
screening procedure according to defined quality
standards, follow-up examinations to confirm or
refute a cancer diagnosis, and initiation and com-
pletion of adequate treatment. In contrast to re-
sults of randomised studies comparing different
drugs, the efficacy achieved in randomised trials of
screening procedures should be considered in the
context of a specific health care system and of the
treatment options available at the time when the
trial was conducted. 
To highlight this we might choose to call this
“programme efficacy”, reflecting what might be
achieved under ideal conditions in a specific health
care environment (table 2). 
Programme efficacy versus effectiveness
In addition, one needs to distinguish effective-
ness from efficacy (table 2). Effectiveness refers to
the benefits achieved in real-life implementation
rather than in the context of a randomised trial,
and can be estimated only from observational stud-
ies. It is commonly expected that the benefits in
real life implementation will tend to be less than
those achieved in randomised trials where condi-
tions tend to maximise the effect of the interven-
tion [28].
Estimates of the programme efficacy 
of mammography screening 
In the last 4 decades, 8 large population-based
and randomised studies on the efficacy of screen-
ing mammography have been conducted in several
countries, most notably the USA, Canada, Sweden
and the United Kingdom, and a series of system-
atic reviews have been conducted to obtain a sum-
mary of the efficacy of screening mammography
(table 5) [6, 10–12, 14, 23, 29, 30]. Unsurprisingly,
the estimated relative risk for breast cancer mor-
tality – comparing the trial groups systematically
invited to mammography screening with the group
not systematically invited – was influenced by the
rationale and decision about which trials to include
in calculating the summary relative risk. Reviews
including most of the trials estimate a relative risk
of death from breast cancer of between 0.71 and
0.79, corresponding to a mortality reduction of
21–29%. Solid evidence has therefore accumu-
lated from randomised studies that systematic and
regular invitation of women aged 50–69 to mam-
mography examinations reduces breast cancer
mortality. The best estimate of the magnitude of
the reduction achieved in randomised studies is
25%, as summarised in 2002 by different expert
meetings and the International Agency for Re-
search on Cancer [23, 31]. This represents pro-
gramme efficacy based on a comparison of women
systematically invited to mammography with
those not systematically invited. This is likely to be
an underestimate of the mortality reduction
achieved for women who actually participate in
mammography screening, since not all those in-
vited will undergo mammography and not all those
not invited will not undergo mammography [32]. 
These beneficial results were achieved in pro-
grammes incorporating tight quality controls. The
challenge today is to evaluate the effectiveness of
population-based breast cancer screening pro-
grammes in the routine health care environment.
The impact on breast cancer mortality is a crucial
indicator of effectiveness. In addition, early indi-
cators of performance are needed to ascertain
whether adjustments are required to a screening
programme in the early stages or during continu-
ous operation of the programme.
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Term Definition
Efficacy The extent to which a specific intervention, procedure, regimen or service produces 
a beneficial result under ideal conditions. Ideally, the determination of efficacy is based 
on the results of a randomised trial.
Programme The extent to which a specific and specified series of multiple measures and procedures 
efficacy produces a beneficial result under ideal conditions. Ideally, the determination 
of programme efficacy is based on the results of a randomised trial.
Effectiveness The extent to which a specific intervention, procedure, regimen, or service, 
when deployed in the field in routine circumstances, does what it is intended to do 
for a specified population.
Programme The extent to which a specific and specified algorithm of measures and procedures, 
effectiveness when deployed in the field in routine circumstances, does what it is intended to do 
for a specified population.
Table 2
Definitions. Distin-
guishing efficacy,
programme efficacy
and population effec-
tiveness (adapted
from [79]).
Screening in Europe and other countries
In Europe the first organised screening pro-
grammes were begun between 1986 and 1989 in
the Nordic countries and the United Kingdom
[33]. These programmes were expanded to na-
tionwide programmes in 1997 and 1996 in Sweden
and the United Kingdom respectively. Additional
nationwide programmes currently exist in Aus-
tralia, Canada, Finland, France, Iceland, Israel,
Luxembourg and the Netherlands. In most Euro-
pean countries regional programmes or pilot proj-
ects were implemented in the late 80s and 90s ([9]
p. 49). Breast cancer screening in the USA is op-
portunistic, except for some programmes organ-
ised within health care plans. The majority of these
programmes target women between the ages of 50
and 69 for screening [34].
Indicators of performance
Several indicators of performance can be used
to predict the final reduction in breast cancer mor-
tality that is likely to be achieved with the current
level of screening performance. They also serve to
keep to a minimum the rate of false-positive mam-
mograms and the rate of unnecessary biopsies.
Performance indicators include parameters such as
participation rate, age-specific or age-standardised
cancer detection rate, interval cancer rate, stage of
distribution of screen-detected cancers, rate of ad-
vanced cancers, and the benign:malignant biopsy
ratio. The European guidelines for performance
give operational definitions and target values for
various performance indicators and are the stan-
dard against which European mammography
screening programmes, including the Swiss pro-
grammes, must be assessed [35, 36]. It is essential
that mammography screening be conducted in a
programmatic context to allow systematic assess-
ment and continuous evaluation of performance
indicators, and the availability of population-based
cancer registry data for assessment of the rates of
interval and advanced cancers is crucial.
Breast cancer mortality
A reduction in breast cancer mortality due to
a population-based screening programme takes
many years to evolve and is difficult to estimate.
First, screening programmes usually take a long
time to cover the whole target population. Second,
programme effectiveness increases with the learn-
ing process among the staff involved. Third, na-
tional statistical data are diluted by deaths related
to cancer diagnosed before the introduction of
screening and cancers diagnosed among women
undergoing opportunistic screening. If record
linkage to a cancer registry is available, “refined
breast cancer mortality” can be calculated which
excludes deaths among women in whom cancer
was diagnosed before the start of screening or, de-
pending on the registry’s data collection, among
women not actually screened. Fourth, even in the
absence of screening effects breast cancer mortal-
ity trends may be affected by changes in the preva-
lence of breast cancer risk factors and hence in
breast cancer incidence, by improvements in treat-
ment, and by changes in coding of death certifi-
cates [37, 38]. A further complicating factor is that
screening and treatment may not independently
affect breast cancer mortality.
National breast cancer incidence and mortal-
ity trends have recently been analysed in 16 Euro-
pean countries [5]. Decreases in breast cancer mor-
tality were observed in countries with national
screening programmes implemented at an early
stage, i.e. the UK, Sweden and the Netherlands. In
some countries with screening programmes, de-
creases in mortality started before screening was
introduced, and decreases also occurred in non-
screened age groups and in some countries with-
out national screening programmes. Nevertheless,
more refined analyses have been conducted for
individual countries and regions, in an attempt to
differentiate between screening and other factors
influencing mortality and to assess the impact on
women invited to screening or actually screened.
These analyses indicate a decrease in recent breast
cancer mortality rates that is at least in part attrib-
utable to screening (see appendix on results in
European countries). 
What to expect from population-based
screening programmes?
Studies on the effectiveness of population-
based mammography screening programmes, in-
cluding those based on modelling of breast cancer
mortality from performance indicators, have so far
resulted in estimates of 5–10% reductions in breast
cancer mortality in the target population due to
screening ([9] p. 134). The effects are expected to
increase with the time elapsed since initiation of
various national and regional programmes. The
size of the maximum attainable reduction in breast
cancer mortality will obviously not only depend on
programme performance but also on factors such
as the rate and quality of opportunistic screening
before the programme started.
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Effectiveness of population-based mammography screening programmes 
The vast majority of women undergoing
mammography screening are healthy and there-
fore cannot derive a direct health benefit from
screening. The major categories of possible ad-
verse effects are, on the one hand, false-positive
results and over-diagnosis, and, on the other, false-
negative results and delayed diagnosis and treat-
ment of breast cancer due to a false reassurance
after negative or false-negative mammograms.
These adverse effects relate to the limits of sensi-
tivity and specificity for two-view mammography,
which vary considerably in population-based set-
tings with ranges for two-view mammography of
70–95% for sensitivity and 90–97% for specificity
[17] (see table 3). Both test characteristics vary with
the round of screening and characteristics of the
women screened, and are lower in younger
women. Additionally, reader characteristics [39,
40] also modify sensitivity and specificity, with vol-
ume being one aspect that is regulated in mam-
mography quality control guidelines ([36] p. 153)
and double-reading being recommended to in-
crease both sensitivity and specificity.
False-positive results
The harm of false-positive mammograms re-
lates to additional testing and invasive procedures
which cause psychosocial stress as well as generat-
ing health care costs which would not have arisen
in the absence of screening [41, 42]. Depending on
the specificity achieved in screening mammogra-
phies in different settings and countries, a woman
has on average a 3–10% likelihood of a false-pos-
itive result with each mammogram [17]. Because
women are screened repeatedly, a woman’s risk of
having a false-positive mammogram increases over
time, and one US study estimated that about half
of the women screened annually in certain US set-
tings will have a false-positive result after 10 mam-
mograms [18, 43]. If we apply an estimate of 4–6%
for the likelihood of a false-positive result of
screening mammograms to a biennial screening
schedule, we can expect that after 10 years (five
rounds) of screening 18.5–26.5% of women
screened will have had a false-positive mammo-
gram necessitating further evaluation and
2.4–3.4% will have had a biopsy with a benign di-
agnosis (table 4). The potential for reducing recall
and biopsy rates was shown in a recent comparison
of mammography screening programmes in the
United States and the United Kingdom [44]. The
recall and open biopsy rates after screening mam-
mograms were twice as high in the US as in the
UK, but cancer detection rates were similar.
European research into strategies to decrease
false-positive rates is ongoing and includes alter-
ation of hormone use before the mammogram,
screening during the luteal phase of the menstrual
cycle, the establishment of explicit goals for recall
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Adverse effects of mammography screening and cost-effectiveness
Characteristic Sensitivity Specificity
Overall 70%–95% 90%–97%
Screening round
First somewhat higher lower 
Subsequent somewhat lower higher
Age 
younger (40–49) lower lower
older (50–69) higher higher
Table 3
Sensitivity and speci-
ficity of screening
mammography for
early detection of
breast cancer in
women aged 50–69
years estimated from
randomised trials
(based on three sys-
tematic reviews
[10, 16, 17]).
biennial 
(5 mammographies)
Women with 1 or more mammograms needing additional evaluation1 1850–2650
Women with 1 or more benign biopsies (needle or open)1 240–340
Women who would have developed breast cancer regardless of screening2 200
Women who are diagnosed with ductal carcinoma in situ3 50
Women who die of breast cancer when no screening is performed2 60
Women who will not die of breast cancer due to mammography screening4 3–12
Number needed to invite to screen for ten years to prevent one death 833–3333
due to breast cancer
The following assumptions were used where indicated:
1 For the occurrence of positive mammograms and of performed biopsies we assumed a false-positivity 
of screening mammography of 4–6% and a biopsy rate of 0.8–1% (first round) and 0.4–0.6% 
(subsequent rounds) [19, 35]. The estimates of the number of women with a positive mammogram 
were rounded to the nearest 50.
2 In the 50–55 age group an age-specific breast cancer incidence of 200 per 100 000 women and an
agespecific breast cancer mortality rate of 60 per 100 000 were assumed based on weighted averages 
of the 45–54, and 55–64 age-specific rates available from the International Agency for the Research 
on Cancer (in Globocan [www.iarc.fr]).
3 This is based on Fletcher’s review [52], and assuming that ductal carcinoma in situ detected 
in mammography screening is of the order of 25% of the breast cancers that would have developed 
regardless of screening.
4 Based on a reduction of breast cancer deaths due to mammography screening for real-life 
implementations estimated to be between 5 and 20% [67].
Table 4
Estimated outcomes
among 10 000
women starting at
age 50–55 to undergo
mammography
screening every two
years for 10 years.
rates in a programmatic context, the availability of
a baseline mammogram and the training of radiol-
ogists in the interpretation of screening mammo-
grams ([9] p. 144, and [18]).
Overdiagnosis
Overdiagnosis refers to the detection of can-
cers that would never have been found were it not
for the screening test. These cancers cause unnec-
essary anxiety (associated with a diagnosis of po-
tentially fatal disease) and unnecessary treatment.
Estimates range from 5–25% of cancers detected
at mammography representing an overdiagnosis
([9] p. 176, and [15]). Evidence supporting the con-
cept of overdiagnosis stems from randomised tri-
als where an elevated breast cancer incidence per-
sists in the screened group, as well as from national
breast cancer incidence data. Results from the
Canadian National Breast Screening Study and in-
cidence data from populations in which breast can-
cer screening has been implemented provide no
evidence that the rising incidence rates of DCIS
have been accompanied by a decrease in the inci-
dence of invasive cancer. This is what would be ex-
pected if a substantial proportion of cases of DCIS
were destined to progress to invasive breast cancer
([45], and [9] p. 149). Furthermore, many more
breast cancers are found in autopsy studies than
will ultimately matter to women ([9] p. 146, and
[18]). Ductal carcinoma in situ, which accounts for
about 9–21% of cancers detected by screening in
Europe, has an uncertain natural course but trig-
gers invasive treatment including mastectomy [18,
46]. This is the likely explanation for the higher
rate of mastectomies in the screened groups re-
ported by Olsen and Gøtzsche [11, 12]. While
detection of DCIS is probably one of the benefits
derived from breast cancer screening, it remains
unclear what proportion of DCIS actually exhibit
the potential to progress to invasive cancer. In the
future, genomic analysis of breast lesions may
improve the identification of subgroups with dif-
ferent potential for progression and allow targeted
intervention. 
Psychosocial consequences 
Women who do or do not want to participate
in mammography programmes may also experi-
ence adverse psychological, social, and financial
consequences, and these must also be considered
side effects [41, 42, 47, 48].
Earlier diagnosis means that women must live
longer knowing that they have a potentially life-
threatening disease. This is balanced only for some
women by less intensive surgery and improved sur-
vival or cure. Thus the immediate negative impact
on quality of life should be weighed against any
prolongation of life [9, 10, 43, 49]. 
Necessity of adequate information
Ultimately decisions about screening should
be made by the women themselves in consultation
with their physician [50–52]. To make this deci-
sion, women need to be well informed concerning
both the benefits and the potential adverse effects
of screening mammography. Information must be
offered in an understandable fashion [46, 52, 53].
Information pamphlets on mammography screen-
ing [54] often report the benefits of mammogra-
phy screening chiefly in terms of relative risk re-
duction instead of absolute risk reduction and
rarely explicitly state the limitations of mammo-
grams; misconceptions about the likely results and
benefits of mammography are therefore wide-
spread [55, 56]. In a recent survey among women
in four countries, including Switzerland, we found
that a majority of women believed that screening
prevents or reduces the risk of contracting breast
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Author of study Included trials Methods for Relative risk of breast 
and year of meta-analysis cancer mortality 
publication (95% confidence interval)
Nystrom et al. 1993 [29] All trials conducted in Sweden Analysis of pooled individual 0.71 (0.57–0.89)
participant data 
Kerlikowske et al. 1995 [30] Summary of 8 trials1) Fixed effects 0.74 (0.66–0.83)
Gøtzsche & Olson 2000 [6] Malmö and Canada Fixed effects 1.04 (0.84–1.27) *
(all other excluded)
Gøtzsche & Olson 2001 Malmö and Canada Fixed effects 0.94 (0.77–1.15) **
[11, 12] (all other excluded)
Nystrom et al. 2002 [14] All trials conducted in Sweden Analysis of pooled individual 0.79 (0.70–0.89)
participant data 
Humphrey et al. 2002 [10] Summary of 8 trials1) Bayesian random-effects model 0.78 (0.70–0.87)
IARC review [23] All 8 trials plus the Finnish Presumably fixed effects 0.75 (0.67–0.85)
national programme are 
described ([23] p. 93) but 
quantitative summaries are 
based on the Swedish trials 
and the Finnish programme
* Results only reported for all age groups combined: Malmö study recruited women aged 45–49, 
and the Canadian trials women aged 40–59.
** Results for women age 50 or over.
1) The 8 trials include: Health insurance plan study in New York, Canada 1 and Canada 2 study, Edinburgh study, 
Göteborg study, Stockholm study, the two-county study in Kopparberg and Ostergötland, the Malmö study (Malmö I).
Table 5
Systematic reviews
of randomised trials
of screening mam-
mography among
women over 50 and
efficacy estimates for
follow-up of at least
10 years.
cancer, that screening at least halves breast cancer
mortality, and that 10 years of regular screening
will prevent 10 or more breast cancer deaths per
1000 women [56]. The contribution of high par-
ticipation rates to the success of population-based
mammography screening programmes must not
bias the information that women are provided with
[57].
Cost-effectiveness
Questions need to be answered regarding the
efficient use of resources in comparison with other
population-based measures in primary and sec-
ondary prevention [58, 59]. The estimated costs
per year of life gained depend on the incidence of
the disease, the quality of the screening pro-
gramme, the participation rate achieved, and the
form and cost structure of the healthcare system
[59, 60]. If cost estimates for Germany are appli-
cable to Switzerland, then long-term mammogra-
phy screening programmes are associated with
costs of CHF 15,000 to 20,000 per year of life
gained [59, 61]. For the USA the estimated costs
are somewhat higher [58]. This is plausible, given
that in the US annual mammography screening is
recommended [62]. Even if the absolute cost esti-
mates are not applicable to Switzerland, the US
study by Coffield contains a useful  comparison
with other population-based healthcare measures.
Colon cancer screening appeared to be more cost-
efficient than mammography screening, but costs
per quality-adjusted year of life gained in mam-
mography screening were of the same order of
magnitude as for cervical carcinoma screening
[58]. For Switzerland, cost-effectiveness data on
opportunistic mammography screening, which is
at least in part paid by health insurance, are lack-
ing. 
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The Swiss situation
Breast cancer mortality in Switzerland
As in other countries with and without estab-
lished mammography screening programmes [1, 4,
5], breast cancer mortality rates in Switzerland in
the 50–79 age group decreased by some 25% be-
tween 1990 and 2000 (figure 1). This decline began
in all language regions well before the launch of
systematic mammography screening programmes
in the cantons of Vaud, Geneva and Valais in 1999
(figure 2). Several factors may have contributed to
this decline. 
First, part of the decline is attributable to
changes in cause-of-death coding introduced by
the switch from International Classification of
Diseases (ICD)-8 (up to 1994) to ICD-10 (starting
1995) by the Swiss Federal Office of Statistics [38,
63]. The change to ICD-10 classification rules
meant that reported cancer diagnoses on the death
certificate less frequently resulted in attributing
death to cancer as the primary cause, especially
when other likely causes of death were recorded.
The effect of this is obvious in the 80-and-over age
group, with a fall of 15% from 273 per 100000 in
1994 to 232 per 100000 in 1995. If all the diag-
nostic information on the death certificates is in-
cluded then the time trends before 1990 appear
more steady and the decline since the early 1990s
is less impressive (figure 1).
Second, treatment developments have redu-
ced the risk of recurrence and improved outcomes
in metastatic disease. Breast cancer mortality has
decreased in women aged 35–49 as well as in all age
groups combined. This is indicative of improved
survival due to advances in treatment of the disease
[5, 37], as Swiss oncologists rapidly adopted the
conclusions of the Early Breast Cancer Trialists’
Collaborative Group on prescribing tamoxifen in
breast cancer treatment [64] (personal communi-
cation Monica Castiglione). 
Third, opportunistic screening mammogra-
phy in Switzerland has become more common. Ac-
cording to the 1997 national health survey, 47%
(95% CI: 45–48%) of Swiss women over 40 had
undergone at least one mammography examina-
tion. Although these proportions were comparable
between urban and rural areas, wide differences
were observed between age groups and linguistic
areas [65]. While the figures represent an overes-
timation for screening mammography (approxi-
mately 25% of these mammograms were probably
performed for diagnostic purposes), the differ-
ences between linguistic areas, most prominent for
the 40–79 age group, are very probably influenced
by prescription and attitudes of physicians to
screening mammography [66]. The differences
existed before the onset of the cantonal screen-
ing programmes in the cantons of Vaud, Geneva
and Valais in 1999.
The first Swiss mammography pilot pro-
gramme was established in 1993 and operated until
1998 in three districts of the French-speaking can-
ton of Vaud for women aged 50–69 [35]. When it
started the canton of Vaud had one of the highest
self-reported mammography screening rates in
Switzerland, with approximately 60% of ever-
users and nearly 20% of annual users among
50–69-year-old women. The results from this first
Swiss pilot programme supported the feasibility
and acceptability of an organised mammography
screening programme in the liberal Swiss health-
care system, where routine opportunistic screen-
ing exists. In view of the results of the pilot proj-
ect the programme was expanded to the whole
canton of Vaud and screening programmes were
implemented in two additional Swiss cantons,
Geneva and Valais, in 1999 [35]. 
The higher prevalence of mammography use
in western Switzerland and the introduction of
mammography screening programmes in the can-
tons of Vaud, Geneva and Valais coincides with a
somewhat earlier decrease and a lower breast can-
cer mortality rate in these three cantons in the
years before the start of the programmes (figure 2).
It may be speculated that the standard of care, in-
cluding secondary prevention, for breast cancer is
generally higher in cantons that were able to set up
a population-based screening programme.
Finally, it is difficult to estimate precisely by
how much cause-of-death coding, treatment de-
velopments and use of screening mammography
have contributed to the observed decline in breast
cancer mortality in Switzerland. We believe, how-
ever, that increased mammography since 1990 may
have contributed only marginally and that the
main factors were treatment developments and
changes in cause-of-death coding.
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Figure 1
Breast cancer mortal-
ity rates (per 100 000
female population) 
in Switzerland by age
group and calendar
year for Swiss na-
tionals versus rates
with mention of
breast cancer irre-
spective of primary
cause of death. Rates
within age groups
are age-standardised
to the Swiss female
population at the 
end of 1990. Arrow
“changes in ICD cod-
ing rules” indicates
the change from
cause-of-death cod-
ing according to the
International Classifi-
cation of Diseases
(ICD)-8 (up to 1994)
to ICD-10 (starting
1995) and a simulta-
neous change in pri-
oritising the primary
cause of death by the
Swiss Federal Office
of Statistics. Arrow
“start of cantonal
mammography
screening pro-
grammes” indicates
the start of the mam-
mography screening
programmes in the
cantons of Geneva,
Vaud and Valais 
in the period
1998–2000.
Conclusions
After forty years in the conduct and interpre-
tation of clinical trials, various international expert
teams recently concluded that high quality mam-
mography screening programmes offered to
women aged 50 and over reduced breast cancer
mortality by about 20–30%, the effect being de-
pendent on compliance, coverage, prevalence of
opportunistic screening, the quality of mammog-
raphy and other factors [9, 14, 31, 62]. At the Milan
Global Summit on Mammographic Screening in
2002 the international experts concluded that doc-
tors and women can be confident that participa-
tion in organised screening programmes with rig-
orous quality assurance standards is of benefit with
regard to breast cancer mortality, provided appro-
priate diagnostic investigation and treatment are
available [31]. 
Evidence is accumulating from several coun-
tries that organised mammography programmes
(implemented outside randomised studies) may
reduce breast cancer mortality in the target age
group. Experience in European countries suggests
that, in the long term, a reduction of about 20%
can be achieved in the target population, but
achieved reductions may vary substantially from
country to country, resulting in a wide range of
programme effectiveness estimates of 5–20% [67,
68]. It is likely and plausible that long-term achiev-
able effectiveness is lower than if mammography
screening is opportunistic rather than anchored
within an organised programme. 
Crude analysis of trends in overall national
breast cancer mortality is an inadequate tool for es-
timating the risk-benefit profile of mammography
screening. Country-specific estimates regarding
the benefit of screening mammography depend on
the availability of data from organised screening
programmes and cancer registries, in addition to
national mortality statistics. Such data are not cur-
rently available for most of Switzerland where or-
ganised screening programmes exist in only three
cantons – all in the French-speaking part of the
country – and where nine cancer registries cover
only 13 of the 26 cantons. The balance of benefi-
cial and adverse effects of mammography screen-
ing is considered favourable in countries that have
established tightly organised mammography pro-
grammes (e.g. the Netherlands) but is likely to be
less favourable where mammography screening is
opportunistic within a fragmented health care
setup without a systematic quality control mecha-
nism. In Switzerland we are now confronted with
growing regional disparities in access to screening
mammography under systematic quality control.
These disparities are very likely to lead to growing
differences in the net balance of beneficial and
adverse effects of screening mammography in
Switzerland. To correct these developments ap-
propriate public health measures are needed and
should aim at, first, regulating quality control for
screening mammography, second, monitoring
mammography use, and third, improving the in-
formation on mammography available to women
from health organizations and physicians. Finally,
health insurance cover for screening mammogra-
phy will be re-evaluated by the Federal authorities
in 2007, and we are likely, as in 1996, to be faced
with a similar body of inadequate evidence on
which to decide for or against health insurance
cover for screening mammography in Switzerland. 
Important gaps in the evidence base should
thus be filled by a coordinated research effort. The
current situation, involving the co-existence of sys-
tematic screening programmes and opportunistic
screening and distinct regional differences, pro-
vides a unique opportunity for research into the
merits and drawbacks of the two approaches. Par-
allel to evaluation of the three organised screening
programmes in the French-speaking parts of
Switzerland, the same indicators of performance
should be collected from cohorts of women un-
dergoing opportunistic mammography screening
in these cantons as well as in cantons that are not
covered by organised programmes but operate
population-based cancer registries. Indicators to
be compared between the two situations include:
(1) the percentage of false-positive mammograms
and thus additional diagnostic procedures, (2) the
percentage of cancers occurring among women
within two years of a negative mammogram (in-
terval cancers), (3) average costs of mammography
and additional diagnostic procedures, (4) speciali-
sation and annual volume of mammography
screening by physicians, and (5) women’s knowl-
edge of and satisfaction with mammography
screening. A concerted and open-minded effort by
physicians, radiology units, health insurances and
other health institutions could thus lay the foun-
dation for an evidence-based policy decision in
2007 in favour of an optimum mammography
screening programme in the Swiss context. In the
meantime, non-programmatic approaches to im-
prove the risk-benefit profile of opportunistic
mammography screening should be implemented
in cantons without programmes, most importantly
double-reading of mammograms and develop-
ment and distribution of objective and compre-
hensible information material for women. These
measures of quality assurance not only seem justi-
fied but are necessary in a country with a seemingly
high rate of opportunistic screening on the one
hand, and limited access to mammography screen-
ing programmes for over half the country. 
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Figure 2
Breast cancer mortality rates (per 100 000 fe-
male population) in Switzerland by language
region and calendar time periods for Swiss na-
tionals aged 50–79. Rates are age-standardised
to the Swiss female population at the end of
1990. Calendar years were grouped in the fol-
lowing periods: 1969–72, 1973–78, 1979–82,
1983–85, 1986–88, 1989–91, 1992–94, 1995–97,
1998–2000; grouping before 1983 was re-
stricted by availability of denominator (popu-
lation) data. Arrow “changes in ICD coding
rules” indicates the change from cause-of-
death coding according to the International
Classification of Diseases (ICD)-8 (up to 1994)
to ICD-10 (starting 1995) and a simultaneous
change in prioritising the primary cause of
death by the Swiss Federal Office of Statistics.
Arrow “start of cantonal mammography
screening programmes” indicates the start of
the mammography screening programmes in
the cantons of Geneva, Vaud and Valais in the
period 1998–2000.
Appendix: Results in European countries
United Kingdom
In the United Kingdom National Health Ser-
vice a breast screening programme was introduced
in England and Wales in 1988 for women aged
50–64, with mammography screening every three
years. The first round was not completed until
1995. Blanks et al. [69] compared observed na-
tional breast cancer mortality rates in England and
Wales from 1990 to 1998 with those predicted
from an age-cohort model based on mortality data
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from 1971–1989. 6% (range 5.4–11.8%) of the ob-
served 21% reduction in breast cancer mortality
among women aged 55–69 was attributed to the
first screening round, although this estimate is
based on the assumption that treatment effects do
not vary by age group. However, in the UK the
benefit of tamoxifen has been reported to be
greater for women aged 55–69 than for those aged
50–54 [15]. McCann and colleagues, using data
from the East Anglian mammography screening
programme, compared the distribution of prog-
nostic factors in two groups of cancers: one diag-
nosed before, and one after the first invitation for
screening [70]. They predicted that – by 2004 – the
second round of screening in East Anglia should
reduce breast cancer mortality by around 7% in
women under 55 at diagnosis, and by around 19%
in those aged 55–64, as a result of the more
favourable tumour size, grade and node status of
cancers in the invited study group. 
Sweden
More refined data on changes in breast cancer
mortality are available from the Swedish studies.
No mammography or other breast-cancer screen-
ing took place in Östergötland and Dalarma (for-
merly called Kopparberg) before late 1977, but by
1988 the entire female population aged 40–69 had
been invited to screening [71]. Comparisons of
deaths from breast cancer diagnosed in the 20 years
before (1958–1977) and in the 20 years after
(1978–1997) the introduction of screening
(1978–1997), between women aged 20–39 and
40–69, and between women undergoing screening
and non-participants, allowed estimation of the
direct screening effect and calculation of breast
cancer mortality reduction restricted to screened
women. There was a significant 44% reduction in
breast cancer mortality in women aged 40–69 ex-
posed to screening. Only 18% of the reduction in
breast cancer mortality was attributed to non-
screening factors, with a large percentage of the
mortality reduction attributed to the screening
programme itself. Jonsson et al. [72] compared
counties from all of Sweden and estimated a re-
fined 20% reduction in breast cancer mortality due
to screening in women aged ≥50 after a mean fol-
low up time of 10.6 years. By 1997, screening hav-
ing been introduced nationwide, the effect on
overall breast cancer mortality – not restricted to
breast cancers diagnosed after the introduction of
screening – was estimated to be 5–6%, close to the
observed decrease in breast cancer mortality in the
UK study [69]. 
The Netherlands
Breast cancer mortality is also in decline in the
Netherlands. A national screening programme 
was first introduced in 1988/1989 in Nijmegen/
Utrecht and gradually recruited women aged
50–69, and by 1997 all eligible women had been
invited at least once [73, 74]. Broeders et al. [75]
compared breast cancer mortality in Nijmegen,
where a screening pilot programme for breast can-
cer was introduced in 1975, to rates in the control
city of Arnhem and in the Netherlands as a whole
over a 20-year period. The results suggested a sta-
tistically non-significant 6–16% reduction in
breast cancer mortality due to screening 20 years
after the start of the programme in Nijmegen.
Otto et al. [74] were able to link mortality to the
specific initiation (month and year) of screening in
more than 500 municipalities across the Nether-
lands in order to analyse screening-related changes
in breast cancer mortality in the Netherlands as a
whole. They observed a decline in non-refined
breast-cancer mortality in the 55–74 age group
which was significantly different from 1997 on-
wards, reaching a 20% reduction in 2001 which
they attributed at least in part to the mammogra-
phy screening programme. 
Finland
The Finnish mammography screening pro-
gramme was implemented in 1986. No obvious
change in national trends in mortality from breast
cancer corresponding to the screening programme
was seen in the crude data, but a more refined
analysis allowing identification of individual
women by invitation-to-screening status and by
date of invitation to screening demonstrated that
the refined breast cancer mortality rate by 1992
was 24% lower among women invited to screen-
ing than among those not invited to screening [76,
77]. The data are supported by another, more re-
cent Finnish investigation in Helsinki (population
0.5 million) where the breast cancer screening
programme started in 1986. Antilla et al. [76] ob-
served a 19% decrease in refined mortality in the
screened cohort compared with the death rate in
women of comparable ages in the non-screened
reference cohort.
Florence Region
Paci et al. [78] linked data from the Tuscany
tumour registry and the databank from the Flo-
rence City screening programme which invited fe-
male residents aged 50–69 over the period from
1990–1996 to undergo 2–view, high quality mam-
mography every 2 years. All cases were followed up
for vital status until the end of 1999, resulting in
an average follow-up of 8 years after the start of
the programme. The cumulative number of breast
cancer deaths among cases was divided by screen-
ing and invitation status. The calculated inci-
dence-based mortality ratio, comparing the mor-
tality rate for two periods (1985–1986, 1990–1996;
pre- and during screening), was 0.50 (95% CI:
0.38–0.66); the reduction was 41% among non-in-
vited women and 55% among women invited for
screening. The reduction from the reference pe-
riod of –3.9 deaths per 10000 in the invited women
(and the –4.4 per 10000 fewer deaths among
women actually screened) indicates, when com-
pared with the –2.8 death reduction in the non-in-
vited, that about one third of the reduction in
women exposed to screening is due to the screen-
ing rounds and the other two thirds to other
causes, including therapeutic advances.
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